The difference people actually ask about is shedding. BioRePeel is sold as a peel you do not visibly peel from. The VI Peel is sold on the peeling: the manufacturer's own patient information says you start flaking around day three and keep going for three to four days. BioRePeel is an Italian product, applied and removed in the clinic in a few minutes. The VI Peel is a US branded solution that is left on your face and washed off at home.
Their regulatory positions are different, and both get described wrongly. No chemical peel product is FDA approved. FDA said so in its own words on 30 July 2024: "The agency has not approved any chemical peel products, and consumers should only consider using chemical peel products under the supervision of a dermatologist or licensed and trained practitioner." Neither product is FDA cleared either, because no chemical peel agent has ever been cleared as a device. BioRePeel goes one step further than that: it does not appear in FDA's device registration and listing database at all. It is CE-marked in Europe, which is a separate European route involving a notified body. FDA does not recognize CE marking, and "FDA registered" is not an approval status.
No trial has compared these two, and neither has meaningful independent evidence of its own. BioRePeel has no indexed peer-reviewed studies. The VI Peel has exactly one publication, and it is an uncontrolled, open-label study of 30 people in which the peel was given together with Botox on the same day. A peel can work perfectly well in the clinic and still have no trial behind it. But it does mean that almost everything said about either product comes from the company that sells it.
Neither maker publishes concentrations, so neither product can be independently assigned a depth. Professional-use products are exempt from the consumer ingredient-declaration rules, which is legal and ordinary. VI Peel publishes its ingredient names without percentages. BioRePeel's official site publishes no acid concentration at all. The 35% TCA figure that circulates on reseller pages cannot be traced to the manufacturer or to any regulatory filing, so it should not be relied on.
The maker, CMed Aesthetics, calls it BioRePeelCl3 FND and places it in a "biorevitalization line with peeling effect," used alongside its own follow-on serum and cream. It is applied in the clinic and taken off before you leave.
The solution is applied in the office and stays on your skin. You wash it off yourself at home after the interval your provider specifies, and no makeup or other topical product goes on for the first four hours.
The official product site does not state a TCA percentage, any acid concentration, or a regulatory classification. There is also an unresolved question about whether the product sold in the US is formulated identically to the European stock; that has not been established either way.
That is the manufacturer's own ingredient list for the original VI Peel, without percentages. Precision Plus adds hydroquinone and kojic acid for pigment. Purify adds benzoyl peroxide, kojic acid and hydrocortisone for acne. Original and Advanced have the same published ingredient list as each other.
Depth is a function of the agent, the concentration, the number of coats, how the skin was prepared, how thick it is, and how hard the operator presses. With no published concentration, there is no way to place this product on a depth scale from the outside.
Published classifications put TCA at 35 to 50 percent in the medium-depth range, reaching the papillary dermis (the upper layer of true skin beneath the surface layer), and above 50 percent in the deep range. Since the TCA percentage here is not published, the product cannot be placed on that scale.
A search of FDA's device registration and listing database for BioRePeel returns nothing. In Europe the product carries a CE mark as a medical device, which is a European process. FDA does not recognize CE marking, and FDA publishes its own page explaining that "FDA registered" and "FDA certified" are not approval statuses.
A search of FDA's 510(k) database returns no chemical peel of any kind, and the acids used in peels have no approved drug application. There is no K-number to quote for any peel because no peel has ever been cleared.
No study of BioRePeel has ever been published, and nothing has been published on its marketed biphasic TCA mechanism either. Everything claimed for it rests on manufacturer material.
Roberts and Miller, 2024, in the Journal of Drugs and Dermatology: 30 people, Fitzpatrick I to VI, single-arm, open-label, no control group, no comparator and no blinding. The paper's funding and conflict-of-interest statement are not in the indexed record, so whether the manufacturer was involved cannot be established either way. The intervention was a VI Peel followed by Botox on the same day, and the stated purpose was to check the safety of doing both together rather than to measure what the peel does.
That is the product's main selling point and it is an unmeasured one. No published study has recorded how much, or whether, skin sheds after this product. What clinics report is the manufacturer's own framing.
The manufacturer says peeling usually starts on or around day three and lasts about three to four days, with individual variation. That is patient instruction, not published data.
The manufacturer does not publish a number of sessions or an interval, so the course you are quoted is set by the clinic.
That is a manufacturer protocol, not a dose-finding result. For comparison, published superficial-peel protocols in trials usually run 3 to 6 sessions at 2-week intervals.
Nobody has measured this, in either direction. Visible flaking tells you the surface layer of skin separated and came away. It does not tell you how much repair happened underneath, and no published work links the amount of shedding after a peel to the result you end up with.
So the honest position is narrower than either sales pitch. A product that makes you shed is not automatically doing more, and a product that does not make you shed is not automatically doing less. What can be said is that the VI Peel's own instructions describe a visible, week-long exfoliation, and BioRePeel's do not — and that neither claim has been checked by anyone independent.
The one thing worth being careful about is the phrase "no downtime." It is a claim about your calendar, not a claim about safety or about depth. A product with acid in it can still irritate, still sting, and still leave skin sensitive to sun afterwards.
This is where most pages about BioRePeel go wrong. A CE mark is a European conformity mark. For a medical device it involves a European notified body assessing the manufacturer's documentation. It is a genuine regulatory process, and it is not FDA.
FDA does not recognize CE marking, and there is no automatic conversion between the two systems. So when a clinic page says BioRePeel is "FDA approved," that is incorrect. When it says "FDA registered," that phrase has no regulatory meaning as an approval — FDA publishes a page saying exactly that — and in this case there is no US device listing for the product anyway.
The VI Peel is in a different but not better position. It is a US professional product with no approval, no clearance and no published concentrations. Neither product has been reviewed by FDA for whether it works.
VI Peel states that all of its treatments are safe and effective for all skin tones. That claim has not been tested in a trial. The single published study of the product included Fitzpatrick I to VI, but it had 30 people, no control group, and was not designed to measure pigment safety.
Published guidance is more careful. A 2026 narrative review of treatments in Fitzpatrick IV to VI says superficial peels are frequently used in this group with good satisfaction, medium-depth peels "require caution," and deep peels should be avoided altogether in dark skin. A scoping review of peels in skin of color screened 473 studies and found only 7 that met inclusion criteria — that is the entire evidence base, and it is why no reliable figure exists for how often pigment changes happen with any particular peel.
The direction of the risk is clear even where the numbers are not: the risk of post-inflammatory hyperpigmentation (dark patches left behind after the skin is irritated) rises with the depth of the peel and rises with deeper skin tones. It is worth noting that VI Peel's own aftercare tells people "prone to hyperpigmentation" to avoid exercise for 7 days rather than the usual 72 to 96 hours, which quietly acknowledges that the risk is not the same for everyone.
If you get cold sores, say so when you book, not on the day. Antiviral medicine has to be prescribed and started in advance, because the reactivation happens while the skin is healing and drug levels need to already be therapeutic by then. In the best published data on this — 181 patients having perioral peels or dermabrasion — half of those with a history of cold sores and no prophylaxis had an outbreak afterwards, compared with 8.3 percent of those given standard acyclovir. Notably, 6.6 percent of people with no history of cold sores at all had an outbreak too. Every published protocol starts the antiviral before, or at the latest on, the day of the procedure. None starts it after.
Tell your provider if you have taken isotretinoin (Accutane) in the last six months. That is a labeled precaution and both a US and an international consensus panel have since said the evidence for delaying superficial peels is insufficient — but medium-depth peels were specifically not cleared by the US panel, so this is a conversation to have rather than a rule to assume.
Say if you are allergic to aspirin, hydroquinone or phenol. All three matter for VI Peel, which lists them as contraindications. Also mention immune suppression, autoimmune disease or liver disease, and any active infection or open area of skin.
Ask which product is being used, who is applying it, and what training they have. FDA's own wording is that peels should be used under the supervision of a dermatologist or licensed and trained practitioner. Who may legally apply a peel is set state by state, not federally, and the general line is depth: superficial peels are within esthetician scope in most states, medium and deep peels are medical procedures almost everywhere.
Plan for sun. Applying alpha hydroxy acids to skin measurably increases sun sensitivity — FDA cites studies showing an 18 percent increase in sensitivity to reddening after four weeks of use, with the sensitivity to UV cell damage roughly doubling. FDA's own recommended label wording asks for sun protection during use and for a week afterwards. This is the best-sourced aftercare instruction in the whole subject.
Any of these needs same-day assessment. Peel injuries deeper than intended are documented, including full-thickness burns from misapplied acid.